Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device development projects. The book provides detailed information on the historical developments of migraine pain management, druggable targets, drugs action mechanisms, drugs for acute treatment and preventive care of patients, administration routes, and alternative treatments. This is the ideal reference for academic researchers interested in anti-migraine pharmacology. It will also be a perfect reference for physicians and care professionals involved in the well-being of migraine patients.
Rezensionen / Stimmen
"...offers a thorough overview of the history, pathophysiology, and available treatments for migraine, including both pharmacological and non-pharmacological approaches.... [It] aims to give a thorough understanding of migraine as a disease and the latest advancements in the field of headache medicine,... offers a well-considered framework for those looking to build their foundational understanding of migraine pathophysiology and management,... [and] provides an extensive overview of migraine as a disease.... The writing is well organized, easy to understand, and structured with a logical flow.... written by authoritative figures in the field of headache medicine and contains a comprehensive review of migraine treatment options, book's organization and clarity make it an invaluable resource.... It is an excellent supplement to existing literature and serves as a strong reference for healthcare providers seeking to enhance their understanding of treatment strategies.... recommend[ed] for trainees and practicing clinicians looking to expand their fundamental knowledge on migraine." (c)Doody's Review Service, 2025, Suraj Malhan, DO, MS (Thomas Jefferson University)
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science Publishing Co Inc
Zielgruppe
Produkt-Hinweis
Broschur/Paperback
Klebebindung
Maße
Höhe: 276 mm
Breite: 216 mm
Gewicht
ISBN-13
978-0-443-24705-7 (9780443247057)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Dr. Stephen Shrewsbury recently left Impel Pharmaceuticals where he served as Chief Medical Officer (CMO) from March 2017 and led the development of Precision Olfactory Delivery of DHE through its clinical program and to FDA approval in September 2021. Formerly Stephen was CMO at MAP Pharmaceuticals where he conducted a successful clinical program for an inhaled version of DHE, but it never got approved due to manufacturing issues. Before MAP he was at Chiron Corporation where he was also on the International Pharmaceutical Aerosol Consortium Board of Science. Before Chiron, Stephen spent 9 years with GlaxoSmithKline (last 2 in the US) having moved into the industry in 1993 after 13 years working in the UK's National Health Service. He has also been CMO for several other West Coast (US) biotech companies; has numerous patents; written and published a book, over 40 scientific papers and nearly 200 abstracts
Herausgeber*in
Formerly Impel Pharmaceuticals, USA
Part I: Foundations and historical development of migraine pain management
1. Introduction
2. Neuroanatomy and Neurophysiology
3. Historical overview of migraine product development
4. Comorbidities and their impact on therapies
5. Not all Migraine attacks are the same
6. Challenges and Controversies; Pharmacokinetics, Linguistics, Semantics and Statistics
Part II: Druggable targets
7. CGRP
8. PACAP
9. Src family kinases (SFK) in Migraine
10. Delta opioid receptor system
11. Piezo channels in peripheral trigeminal nociception
12. TRP antagonists
Part III: Drugs - Acute Management
13. Simple analgesics and combination oral products
14. Cannabinoids & Phytochemicals
15. Ergots
16. Triptans
17. Beta blocker (timolol) eye drops
18. Lasmiditan (and the ditan class)
19. Gepants
Part IV: Drugs - Prevention
20. TCAs (Tricyclic Antidepresants), SNRIs, Beta blockers, candesartan, flunarizine
21. Antiseizure orals (gabapentin, topiramate)
22. Onabotulinumtoxin
23. Gepants (for prevention)
24. (CGRP) Monocloncal antibodies
Part V: Administration routes
25. Oral Drugs (including SMEDDS)
26. Inhaled - oral & nasal
27. Subcutaneous/IM/Transcutaneous ("Injectables")
28. IV/Infusion
Part VI: Alternative Management
29. The role of digital platforms and smartphone apps
30. Herbal Medicines
31. Phototherapy
32. Neuromodulation
33. Acupuncture (for episodic and chronic migraine)
34. Manual Therapies
35. Nutraceuticals and Diets
36. Mindfulness
Part VII: Summary & conclusion [Shrewsbury]
37. Final Perspectives: oral/non-oral pharmaceuticals; devices; Complimentary practices
